Invivyd, INC. (IVVD) — 8-K Filings

All 8-K filings from Invivyd, INC.. Browse 45 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (45)

8-K Filing — Apr 9, 2026
Invivyd, Inc. Files 8-K — Dec 23, 2025 Risk: low
Invivyd, Inc. filed an 8-K on December 23, 2025, reporting other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is i
8-K Filing — Nov 24, 2025
8-K Filing — Nov 19, 2025
Invivyd, Inc. Files 8-K Report — Oct 30, 2025 Risk: low
On October 30, 2025, Invivyd, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific financ
Invivyd, Inc. Files 8-K — Oct 6, 2025 Risk: low
Invivyd, Inc. filed an 8-K on October 6, 2025, reporting other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is inc
Invivyd, Inc. Files 8-K: Officer/Director Changes & More — Sep 24, 2025 Risk: medium
Invivyd, Inc. filed an 8-K on September 24, 2025, reporting on events as of September 22, 2025. The filing covers the departure of directors or certain officers
Invivyd, Inc. Files 8-K for Material Definitive Agreement — Aug 22, 2025 Risk: medium
On August 20, 2025, Invivyd, Inc. entered into a material definitive agreement. The company, formerly known as Adagio Therapeutics, Inc., is based in Waltham, M
Invivyd, Inc. Files 8-K on Financials and Operations — Aug 14, 2025 Risk: low
On August 14, 2025, Invivyd, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along with oth
Invivyd, Inc. Files 8-K Report — Jul 2, 2025 Risk: low
Invivyd, Inc. filed an 8-K on July 2, 2025, reporting other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is incorp
Invivyd, Inc. Files 8-K — Jun 26, 2025 Risk: low
Invivyd, Inc. filed an 8-K on June 26, 2025, reporting other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is incor
Invivyd, Inc. Files 8-K on Security Holder Vote Matters — May 20, 2025 Risk: low
Invivyd, Inc. filed an 8-K on May 20, 2025, to report on the submission of matters to a vote of its security holders. The filing does not contain specific detai
Invivyd, Inc. Files 8-K on Financials and Operations — May 15, 2025 Risk: low
Invivyd, Inc. filed an 8-K on May 15, 2025, reporting on its results of operations and financial condition, as well as other events. The filing also includes fi
Invivyd, Inc. Files 8-K — May 12, 2025 Risk: low
Invivyd, Inc. filed an 8-K on May 12, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific financial det
Invivyd, Inc. Faces Delisting Concerns — Apr 25, 2025 Risk: high
Invivyd, Inc. (formerly Adagio Therapeutics, Inc.) filed an 8-K on April 25, 2025, reporting a notice of delisting or failure to satisfy a continued listing rul
Invivyd, Inc. Files 8-K for Material Agreement — Apr 21, 2025 Risk: medium
Invivyd, Inc. announced on April 18, 2025, the entry into a material definitive agreement and the creation of a direct financial obligation. The company, former
Invivyd, Inc. Files 8-K on Officer/Director Changes — Mar 26, 2025 Risk: medium
Invivyd, Inc. filed an 8-K on March 26, 2025, reporting on events as of March 22, 2025. The filing covers the departure of directors or certain officers, the el
Invivyd, Inc. Files 8-K on Financials — Mar 20, 2025 Risk: low
Invivyd, Inc. filed an 8-K on March 20, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and
Invivyd, Inc. Files 8-K — Mar 5, 2025 Risk: low
Invivyd, Inc. filed an 8-K on March 5, 2025, reporting other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is incor
Invivyd, Inc. Files 8-K with Financials — Feb 24, 2025 Risk: low
Invivyd, Inc. filed an 8-K on February 24, 2025, reporting events as of February 21, 2025. The filing primarily concerns financial statements and exhibits, with
Invivyd, Inc. Files 8-K on Financials and Other Events — Feb 3, 2025 Risk: low
Invivyd, Inc. filed an 8-K on February 3, 2025, reporting on its Results of Operations and Financial Condition, Other Events, and Financial Statements and Exhib
Invivyd, Inc. Files 8-K — Jan 27, 2025 Risk: low
Invivyd, Inc. filed an 8-K on January 27, 2025, to report other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is in
Invivyd, Inc. Files 8-K — Jan 10, 2025 Risk: low
Invivyd, Inc. filed an 8-K on January 10, 2025, reporting other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is in
Invivyd, Inc. Files 8-K on Delisting Concerns — Dec 27, 2024 Risk: high
Invivyd, Inc. filed an 8-K on December 27, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company, formerly known as
Invivyd Reports Director Changes and Compensation Updates — Dec 2, 2024 Risk: medium
Invivyd, Inc. filed an 8-K on November 27, 2024, reporting changes in its board of directors and executive compensation arrangements. The filing indicates a dep
Invivyd, Inc. Files 8-K on Financials and Operations — Nov 14, 2024 Risk: low
Invivyd, Inc. filed an 8-K on November 14, 2024, reporting on its results of operations and financial condition, other events, and financial statements. The fil
Invivyd, Inc. Files 8-K — Oct 29, 2024 Risk: low
Invivyd, Inc. filed an 8-K on October 29, 2024, reporting on its results of operations, other events, and financial statements. The company, formerly known as A
Invivyd, Inc. Files 8-K — Sep 23, 2024 Risk: low
Invivyd, Inc. filed an 8-K on September 23, 2024, reporting other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is
Invivyd, Inc. Files 8-K Report — Sep 6, 2024 Risk: low
Invivyd, Inc. filed an 8-K on September 6, 2024, to report other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is i
Invivyd, Inc. Files 8-K — Sep 4, 2024 Risk: low
Invivyd, Inc. filed an 8-K on September 4, 2024, to report other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is i
Invivyd, Inc. Files 8-K — Sep 3, 2024 Risk: low
Invivyd, Inc. filed an 8-K on September 3, 2024, reporting other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is i
Invivyd, Inc. Announces CMO Departure and Interim Appointment — Aug 27, 2024 Risk: medium
On August 27, 2024, Invivyd, Inc. filed an 8-K report detailing the resignation of Dr. David M. Apelian from his role as Chief Medical Officer, effective August
Invivyd, Inc. Files 8-K on Operations and Financials — Aug 14, 2024 Risk: low
Invivyd, Inc. filed an 8-K on August 14, 2024, reporting on its results of operations, financial condition, and other events. The filing also includes financial
Invivyd, Inc. Files 8-K — Jun 14, 2024 Risk: low
Invivyd, Inc. filed an 8-K on June 14, 2024, to report other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is incor
Invivyd Appoints New CMO and COO — May 31, 2024 Risk: medium
Invivyd, Inc. announced on May 30, 2024, the appointment of Dr. Patrick Gilmore as Chief Medical Officer and Dr. David Apelian as Chief Operating Officer. The c
Invivyd, Inc. Files 8-K: Voting Matters & Financials — May 22, 2024 Risk: low
Invivyd, Inc. (formerly Adagio Therapeutics, Inc.) filed an 8-K on May 22, 2024, reporting on matters submitted to a vote of security holders, Regulation FD dis
Invivyd, Inc. Files 8-K on Operations and Financials — May 9, 2024 Risk: low
Invivyd, Inc. filed an 8-K on May 9, 2024, reporting on its results of operations and financial condition, as well as other events. The filing also includes fin
Invivyd, Inc. Files 8-K — May 7, 2024 Risk: low
Invivyd, Inc. filed an 8-K on May 7, 2024, reporting on other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is inco
Invivyd Appoints New CMO & CSO, Discloses Compensation — Apr 12, 2024 Risk: medium
Invivyd, Inc. announced on April 11, 2024, the appointment of Dr. Patrick Gilmore as Chief Medical Officer and Dr. David Apelian as Chief Scientific Officer. Th
Invivyd, Inc. Files 8-K — Apr 4, 2024 Risk: low
Invivyd, Inc. (formerly Adagio Therapeutics, Inc.) filed an 8-K on April 4, 2024, reporting other events and financial statements. The company, incorporated in
Invivyd, Inc. Files 8-K on Financials — Mar 28, 2024 Risk: low
Invivyd, Inc. (formerly Adagio Therapeutics, Inc.) filed an 8-K on March 28, 2024, reporting on its Results of Operations and Financial Condition. The filing in
Invivyd, Inc. Files 8-K on Financials and Operations — Mar 25, 2024 Risk: low
Invivyd, Inc. (formerly Adagio Therapeutics, Inc.) filed an 8-K on March 25, 2024, reporting on events as of March 22, 2024. The filing pertains to results of o
Invivyd 8-K Details Officer Compensation, Corporate Events — Feb 9, 2024 Risk: low
Invivyd, Inc. (formerly Adagio Therapeutics, Inc.) filed an 8-K on February 9, 2024, reporting on various corporate events that occurred on February 5, 2024. Th
Invivyd Files 8-K: Corporate Info Update, Nasdaq Listing Confirmed — Jan 8, 2024
Invivyd, Inc. (formerly Adagio Therapeutics, Inc.) filed an 8-K on January 8, 2024, to update its corporate information, including its current address at 1601 T
Invivyd Files Routine 8-K for Other Events & Exhibits — Jan 3, 2024
Invivyd, Inc. filed an 8-K on January 3, 2024, to report "Other Events" and "Financial Statements and Exhibits." This filing, under SEC File Number 001-40703, i

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX